Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 7—July 2012

Research

Predicting Risk for Death from MRSA Bacteremia1

Mina PastagiaComments to Author , Lawrence C. Kleinman, Eliesel G. Lacerda de la Cruz, and Stephen G. Jenkins
Author affiliations: The Rockefeller University, New York, New York, USA (M. Pastagia); Mount Sinai School of Medicine, New York (L.C. Kleinman, E.G. Lacerda de la Cruz); and Weill Cornell School of Medicine, New York (S.G. Jenkins)

Main Article

Table 1

Multivariable analysis of risk factors for VISA and hVISA infections, New York, New York, USA, 2002–2007*

Risk factor and MRSA strain Odds ratio Adjusted risk ratio (95% CI) Adjusted risk difference (95% CI)†
Age‡
VISA 0.93 0.82 (0.65 to 1.12) –0.020 (–0.080 to 0.007)
hVISA 0.93 0.96 (0.73 to 1.35) –0.003 (−0.050 to 0.013)
Race/ethnicity
Black
VISA 0.90 0.76 (0.35 to 1.57) –0.02 (–0.07 to 0.04)
hVISA 0.90 1.03 (0.44 to 2.13) 0.002 (−0.050 to 0.070)
Hispanic
VISA 0.89 0.87 (0.36 to 1.88) –0.01 (–0.06 to 0.05)
hVISA 0.46 0.62 (0.19 to 1.37) −0.03 (−0.08 to 0.03)
Asian
VISA 1.97 1.79 (0.77 to 3.34) 0.06 (−0.02 to 0.15)
hVISA 1.58 1.65 (0.66 to 3.21) 0.05 (−0.03 to 0.14)
Concurrent condition
Diabetes
VISA 1.42 1.44 (0.78 to 2.59) 0.03 (−0.02 to 0.08)
hVISA 0.69 0.87 (0.48 to 1.48) −0.01 (−0.05 to 0.03)
Chronic hemodialysis
VISA 1.25 1.23 (0.56 to 2.57) 0.02 (−0.04 to 0.09)
hVISA 1.32 1.05 (0.48 to 2.03) 0.004 (−0.040 to 0.060)
HIV
VISA 0.50 0.45 (0.09 to 1.06) –0.05 (−0.090 to 0.004)
hVISA 0.30 0.27 (0.06 to 1.38) −0.060 (−0.100 to −0.008)
Liver cirrhosis
VISA 2.38 3.43 (2.02 to 6.00) 0.14 (0.06 to 0.23)
hVISA 2.55 2.11 (1.06 to 3.87) 0.080 (0.005 to 0.170)
Malignancy
VISA 2.02 1.96 (1.07 to 3.31) 0.070 (0.005 to 0.130)
hVISA 1.37 1.64 (0.87 to 3.07) 0.04 (−0.01 to 0.11)
Other
Nursing home residence
VISA 1.62 1.83 (0.88 to 3.30) 0.060 (–0.009 to 0.130)
hVISA 1.12 0.94 (0.36 to 1.80) –0.005 (–0.060 to 0.050)
Surgical procedure§
VISA 0.50 0.41 (0.20 to 0.76) –0.06 (–0.10 to –0.02)
hVISA 0.79 0.62 (0.32 to 1.02) –0.040 (–0.080 to 0.002)
Prior receipt of vancomycin
VISA 1.87 2.09 (1.25 to 3.67) 0.06 (0.02 to 0.10)
hVISA 0.92 0.97 (0.56 to1.65) −0.002 (−0.040 to 0.040)
Central venous catheter infection
VISA 0.80 0.83 (0.50 to1.36) –0.01 (–0.05 to 0.02)
hVISA 2.09 1.81 (1.13 to 3.10) 0.050 (0.009 to 0.090)

*Results from logistic regression with outcomes and covariates. VISA, vancomycin-intermediate Staphylococcus aureus strains, hVISA, heteroresistant vancomycin-intermediate S. aureus strains; MRSA, methicillin-resistant S. aureus.
†Adjusted risk difference refers to the absolute difference in risk; for example, an adjusted risk difference of 0.10 signifies a 10% increased risk for hVISA, VISA, given that variable.
‡Measures are adjusted odds ratio for a 10-y difference and adjusted risk difference for effect of age 50–60 y.
§Surgical procedures under general anesthesia within the past 3 months.

Main Article

1Parts of the data in this article were presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America Meeting, October 25–28, 2008, Washington, DC, USA; and the 19th European Congress of Clinical Microbiology and Infectious Diseases Meeting, May 16–19, 2009, Helsinki, Finland.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO